International Mesothelioma Conference Will Kick Off at UCLA
Thoracic surgeon and renowned mesothelioma specialist Dr. Robert Cameron will be hosting the 6th International Symposium on Malignant Pleural Mesothelioma on Saturday, Sept. 24, at the UCLA School of Medicine. Cameron, director of the UCLA Comprehensive Mesothelioma Program, is a global leader in the development of the lung-sparing pleurectomy/decortication surgery and a vocal advocate for military veterans who develop the asbestos-related disease. The conference will cover the latest in mesothelioma therapeutics, including novel immunotherapies, gene therapy, upcoming clinical trials and surgical advancements. The purpose is to improve the understanding of multidisciplinary treatment, learn about adjuvant therapy possibilities, raise awareness to various types of immunological therapies, and emphasize the need to treat mesothelioma as a chronic disease. Oncologists, pulmonologists, surgeons, nurses, medical students, mesothelioma advocates, patients and families across the nation will attend to exchange thoughts and ideas. The Mesothelioma Center’s Patient Advocates Karen Selby and Vanessa Blanco will participate, ensuring patients and loved ones who reach out to the organization in the coming months will receive the latest information on mesothelioma treatments. Selby, a registered nurse with a surgical and oncological background, joined The Mesothelioma Center in 2009. “It’s important for us to be there, hearing about the cutting-edge research and learni...
Condition: Mesothelioma Interventions: Drug: Nivolumab Injection; Drug: Ipilimumab Injection Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Bristol-Myers Squibb Not yet recruiting
Conditions: Advanced Solid Cancer; Non Small Cell Lung Cancer; Esophageal Cancer; Ovarian Cancer; Malignant Pleural Mesothelioma Intervention: Drug: APG-2449 Sponsor: Ascentage Pharma Group Inc. Not yet recruiting
Conclusion The safety profile of BV in patients with solid tumors was similar to the known safety profile of BV. In solid tumors, BV had modest activity as a single agent, which was similar to other second-line treatments already available to patients.
ConclusionsThis analysis provides evidence that the risk of mesothelioma does not decrease after cessation of asbestos exposure, while lung cancer risk does.
Joe Abdo1, Christopher S. Wichman2, Nicholas E. Dietz1,3, Pawel Ciborowski4, John Fleegel1, Sumeet K. Mittal1,5 and Devendra K. Agrawal1* 1Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE, United States 2Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States 3Department of Pathology, CHI Health Creighton University Medical Center, College of Medicine, Omaha, NE, United States 4Department of Pharmacology, University of Nebraska Medical Center, Omaha, NE, United States 5Norton Thoracic Institute, St....
Conclusions: EBUS-TBNA mediastinal LN staging may impact significantly management of patients with MPM by detecting mediastinal metastatic disease, therefore, preventing morbidity and mortality of surgical management. PMID: 30963005 [PubMed]
Conditions: Mesothelioma; Mesothelioma, Malignant; Mesothelioma; Pleura; Mesotheliomas Pleural; Mesothelioma Peritoneum; Cholangiocarcinoma; Cholangiocarcinoma Recurrent; Ovarian Cancer; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic Interventions: Drug: TC-210 T Cells; Drug: fludarabine; Drug: cyclophosphamide; Biological: anti-PD1 Sponsor: TCR2 Therapeutics Recruiting
Malignant pleural mesothelioma (MPM) is a rare thoracic solid tumor cancer that has been strongly linked to asbestos exposure. It has a long latency period of at least 20-30 years following exposure, and global incidence is still increasing in countries where asbestos is still in use. Surgical resection for patients with early stage MPM is considered standard therapy and radiation therapy offers only palliative benefit. For patients with advanced disease, combination chemotherapy with Cisplatin and Pemetrexed results in improvement in survival and quality of life, thus constituting the “standard of care”.
Tumor Treating Fields (TTFields) are a clinically applied anti-neoplastic treatment modality delivered via noninvasive application of low intensity, intermediate frequency, alternating electric fields. This therapy is approved for the treatment of patients with glioblastoma and pilot studies have demonstrated the safety as well as preliminary effectiveness of TTFields application in patients with non-small cell lung cancer and mesothelioma. Here we evaluated the potential of TTFields therapy to induce immunogenic cell death (ICD) and evaluate the efficacy of concurrent application of TTFields and anti-PD-1 therapy in murin...
A long-awaited phase III clinical trial of a novel gene therapy could change malignant pleural mesothelioma treatment in the future. The trial, which will include almost 50 locations around the world, opens this month for mesothelioma patients whose standard treatment has stopped working. The gene therapy drug, called TR002, is also a form of immunotherapy. It will be used in combination with gemcitabine chemotherapy in a second-line setting. “We can’t predict what the outcome will be, but we’re very excited about the potential of this treatment, and the fact there may be another drug in the armamentarium...
More News: Allergy & Immunology | Asbestosis | Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Cardiovascular & Thoracic Surgery | Clinical Trials | Conferences | Environmental Health | Gene Therapy | Genetics | Heart | Immunotherapy | Learning | Mesothelioma | New York University | Nurses | Nursing | Students | Universities & Medical Training